Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where S. Di Lollo is active.

Publication


Featured researches published by S. Di Lollo.


Journal of Clinical Pathology | 2003

Guidelines for processing and reporting of prostatic needle biopsies

Theo H. van der Kwast; Carlos Lopes; C. Santonja; C.‐G. Pihl; I. Neetens; Pekka Martikainen; S. Di Lollo; Lukas Bubendorf; Robert F. Hoedemaeker

The reported detection rate of prostate cancer, lesions suspicious for cancer, and prostatic intraepithelial neoplasia (PIN) in needle biopsies is highly variable. In part, technical factors, including the quality of the biopsies, the tissue processing, and histopathological reporting, may account for these differences. It has been thought that standardisation of tissue processing might reduce the observed variations in detection rate. Consensus among the members of the pathology committee of the European Randomised study of Screening for Prostate Cancer (ERSPC) concerning the optimal methodology of tissue embedding resulting in guidelines for prostatic needle biopsy processing was reached. The adoption of an unequivocal and uniform way of reporting lesions encountered in prostatic needle biopsies is considered helpful for decision taking by the clinician. The definition of parameters for quality control of prostatic needle biopsy diagnostics will further facilitate clinical epidemiological multicentre studies of prostate cancer.


British Journal of Cancer | 1989

Combined surgery and chemotherapy for the treatment of primary gastrointestinal intermediate- or high-grade non-Hodgkin's lymphomas.

G. Bellesi; Renato Alterini; Andrea Messori; Alberto Bosi; Franco Bernardi; S. Di Lollo; P. Rossi Ferrini

Fifty-five consecutive patients with primary gastrointestinal intermediate or high grade non-Hodgkins lymphoma were analysed to assess the efficacy of chemotherapy following surgical tumour resection. Histological subtypes were high grade (n = 18), intermediate grade (n = 36) and unclassified (n = 1). The majority of patients had gastric presentation (71%) and localised disease (84%). Surgery consisted of radical resection in 25 patients (45%) and partial or palliative excision in the remaining cases (22 and 8 respectively). Four subjects died within 3 months of surgery, two patients refused adjuvant chemotherapy and 49 completed the postoperative chemotherapeutic programme. Chemotherapy included either Fi2/74 (adriamycin + vincristine + bleomycin + cyclophosphamide + prednisone) or Fi3/74 (adriamycin + VM26 + bleomycin + cyclophosphamide + prednisone). Excluding the group who underwent radical tumour resection, postoperative chemotherapy induced complete remission in 81% of the remaining 30 patients. The 10-year cause-specific survival for the 53 treated patients was 76% (median follow-up 58 months) with a stable curve plateau after 80 months. Proportional-hazard multivariate statistics showed that survival was influenced by type of surgical resection (P less than 0.05) and stage (P less than 0.05), whereas age, sex and histological subtype were not influential. Our data indicate that chemotherapy following surgical resection of gastrointestinal lesion induces long-term remission in primary gastrointestinal lymphomas.


Journal of Clinical Pathology | 1998

Chronic cryptosporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin.

Daniele Dionisio; A Orsi; Gaetana Sterrantino; M. Meli; S. Di Lollo; L Ibba Manneschi; Michele Trotta; M Pozzi; L Sani; Francesco Leoncini

AIMS: To investigate the effectiveness of long term, low dose azithromycin treatment for chronic cryptosporidiosis in patients with AIDS. METHODS: Azithromycin was administered as initial daily treatment to 13 patients with AIDS: 6 patients received 500 mg for 30 to 40 days (mean 35); 3 patients received 1000 mg for 21 to 50 days (mean 37); and 4 patients received 1500 mg for 20 days. Nine of the 13 patients were also given low dose maintenance treatment with different schedules of azithromycin for 30 to 360 days (mean 129). Patients were monitored, during and after treatment, for parasite shedding in stool and for daily stool frequency and body weight. All but one patient had severe immunodeficiency. RESULTS: Long term, low dose maintenance treatment was associated with major clinical and parasitological benefits: there was probable eradication of infection in 2 patients, and 7 patients showed a complete response with persistent high decrease (5 patients) or clearance (2 patients) of parasite in stool. The drug was well tolerated, and there was no relapse either during treatment or during follow up (up to 21 months). These results were more impressive than those observed after the short term initial course of azithromycin, which was unable at any tested dose to achieve parasite clearance in stool (except in the patient with less advanced immunodeficiency) or to prevent relapse in 3 patients who discontinued treatment. Reversible side effects occurred with the 1500 mg daily dose. CONCLUSIONS: Long term, low dose azithromycin is well tolerated and may induce stable remission of chronic cryptosporidiosis in patients with AIDS. It may lead to probable eradication of the infection in some patients, even those with severe immunodeficiency.


European Journal of Cancer | 2010

Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer

Marita Laurila; T.H. Van Der Kwast; Lukas Bubendorf; S. Di Lollo; C.‐G. Pihl; Stefano Ciatto; Jonas Hugosson; Liisa Määttänen; Monique J. Roobol; Paula Kujala

THE AIM OF THE STUDY This article presents the incidence of prostate cancer, isolated high grade prostatic intraepithelial neoplasia (PIN) and atypical lesions suspicious for prostate cancer (LSPC) during subsequent screening rounds in the centres of five of the countries participating in the European Randomized Study of Screening for Prostate Cancer (ERSPC). The incidence and predictive value of high grade PIN and LSPC for prostate cancer in subsequent biopsy following these diagnoses were evaluated. PATIENTS AND METHODS Study group consisted of 56,653 screened men in the ERSPC centres of Finland, Italy, Netherlands, Sweden and Switzerland, who underwent 3-7 screening rounds at 2-4 year interval. Data for prostate cancer were obtained from the ERSPC central database. Data for high grade PIN and LSPC were gathered from each ERSPC centre. Detection rates of subsequent prostate cancer in the first re-biopsy after these diagnoses were determined. RESULTS The average cancer detection rate was 3.5%, 3.2% and 3.5% for the completed rounds 1, 2 and 3, respectively, in all five centres. Incidence of high grade PIN increased from 1.5% in the first round to 5.0% in the third round, varying among centres in the first round between 0.8% and 7.6%. The cancer detection rate in the first re-biopsy after the diagnosis of high grade PIN was 12.9%. Incidence of LSPC was 2.4%, 2.7%, 2.2% and 2.6% in the first, second, third and fourth round, respectively. The cancer detection rate at the first re-biopsy after the diagnosis of LSPC was in average 33.8%. CONCLUSIONS Cancer detection rate was stable during the three screening rounds. The wide variation in frequency in particular of high grade PIN among the ERSPC centres suggests a considerable inter-observer variation. The average comparatively low detection rate of isolated high grade PIN in the first screening round may be screening-related, while its consistent increase during three screening rounds could be the consequence of a.o. previous screening and ageing of the population. The observed low risk of prostate cancer after isolated high grade PIN in this screening setting is in line with the current recommendation to abstain from early repeat biopsies after this diagnosis. The association of LSPC with high incidence of prostate cancer in re-biopsies confirms the need for early repeat biopsies and follow-up of these men. The low percentage of LSPC (<3% of biopsies) throughout all rounds is reassuring as it limits the biopsy burden in a screening setting.


Annals of the Rheumatic Diseases | 2010

Severe fibrotic changes and altered expression of angiogenic factors in maternal scleroderma: placental findings

Lidia Ibba-Manneschi; Mirko Manetti; Anna Franca Milia; Irene Miniati; Gemma Benelli; Serena Guiducci; Federico Mecacci; G. Mello; S. Di Lollo; Marco Matucci-Cerinic

Objective: Pregnant women with systemic sclerosis (SSc; scleroderma) have an increased risk of premature delivery and small full-term infants. During placental development, angiogenesis and vascular remodelling are essential for a successful pregnancy outcome. An analysis was made of the pathological changes and expression of angiogenic factors in SSc placentas. Methods: Placenta biopsies were obtained from three patients with SSc and four healthy uncomplicated pregnancies after delivery at 34–38 weeks of gestation. The sections were stained with Masson’s trichrome and phosphotungstic-acid-haematoxylin and immunostained for connective tissue growth factor (CTGF), α-smooth muscle actin (α-SMA), vascular endothelial growth factor (VEGF), placenta growth factor (PlGF) and receptors VEGFR-1 and VEGFR-2. Results: The pathological findings were signs of decidual vasculopathy, increased syncytiotrophoblast knotting, placental infarcts and villous hypoplasia. Severe and diffuse perivascular and stromal fibrosis of decidua and chorionic villi, and extensive deposition of fibrinoid material around decidual vessels and in intervillous spaces were observed. Strong CTGF expression in the vessel wall, decidual cells and fibroblasts and α-SMA+ myofibroblasts were found. VEGF and VEGFR-2 expression was stronger in SSc than in healthy placentas, while VEGFR-1 expression was similar to controls. PlGF immunopositivity was weaker in SSc. Conclusion: In SSc placentas, severe fibrosis and abnormal vascular remodelling were detected. This may result in reduced blood flow leading to deep sufferance of maternal placenta and possible premature delivery.


Annals of the Rheumatic Diseases | 1989

Pachydermoperiostosis (primary hypertrophic osteoarthropathy): report of a case with evidence of endothelial and connective tissue involvement.

Marco Matucci-Cerinic; S Cinti; M Morroni; Torello Lotti; G Nuzzaci; E Lucente; S. Di Lollo; M Ceruso; M. Cagnoni

A case of pachydermoperiostosis characterised by the presence of finger clubbing, periostosis, sweating of hands and feet is described. Modifications of capillaroscopic pattern and of arteriovenous anastomoses are reported. The periungual border and finger tip tissue showed diffuse endothelial hyperplasia, hyalinosis, and sclerosis with packing of collagen fibres. Electron microscopy showed hypertrophic and activated endothelia (numerous and hypertrophic Golgi complexes, several Weibel-Palade bodies, vesicles of micropinocytosis, and glycogen particles), the basal membrane thickened and reduplicated, perivasal infiltrate in superficial derma, reticulation and segmentary reduplication of basal membrane in arteriovenous shunt. In the perineural connective tissue numerous Luse bodies (long spacing collagen) were evident. The data indicate that in the early phase of pachydermoperiostosis morphological endothelial and collagen fibre abnormalities are present, though there is a normal peripheral blood flow.


BJUI | 2003

Consistency of prostate cancer grading results in screened populations across Europe.

T.H. van der Kwast; Monique J. Roobol; Mark F. Wildhagen; Paula M. Martikainen; L. Määtänen; C.‐G. Pihl; C. Santonja; Lukas Bubendorf; I. Neetens; S. Di Lollo; Robert F. Hoedemaeker

To assess the consistency of grading outcome among seven of eight participating centres of the European Randomised Screening Program of Prostate Cancer (ERSPC), a multicentre randomized trial intended to detect a difference in prostate cancer‐related mortality between screened participants and a control group. Currently, tumour stage and grade in prostatectomy specimens represent the most predictive variables for biological behaviour. In prostate needle biopsies the tumour grade is a strong factor for deciding therapy.


BJUI | 2003

Report of the Pathology Committee: false-positive and false-negative diagnoses of prostate cancer

T.H. van der Kwast; Carlos Lopes; Paula M. Martikainen; C.‐G. Pihl; C. Santonja; I. Neetens; S. Di Lollo; Robert F. Hoedemaeker

T.H. VAN DER KWAST, C. LOPES*, P.M. MARTIKAINEN†, C.-G. PIHL‡, C. SANTONJA¶, I. NEETENS§, S. DI LOLLO** and R.F. HOEDEMAEKER Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands, *Department of Anatomy-Pathology, Instituto Português de Oncologia de Francisco Gentil, Porto, Portugal, †Department of Pathology, Centre for Laboratory Medicine, Tampere, Finland, ‡Department of Pathology, Sahlgrenska University Hospital, Östra, Göteborg, Sweden, ¶Department of Anatomy-Pathology, Hospital Universitario de Getafe, Getafe (Madrid), Spain, §Department of Pathology, Middelheim Hospital, Antwerp, Belgium, and **Department of Pathology, University of Florence, Italy


Leukemia & Lymphoma | 1996

A new protocol (MiCEP) for the treatment of intermediate or high-grade non-hodgkin's lymphoma in the elderly

G. Bellesi; Luigi Rigacci; Renato Alterini; Franco Bernardi; S. Stefanacci; F. Innocenti; I. Fusco; Giovanni Longo; S. Di Lollo; P. Rossi Ferrini

Age has proved to be an important prognostic factor in patients with advanced non-Hodgkin lymphoma (NHL) and these patients require intensive and extensive therapy. Dose-reduction and therapy attenuation have reduced treatment-related toxicity, but have also decreased therapeutic efficacy. Between January 1990 and December 1992, 41 previously untreated patients, 65 years with stage 2-4 intermediate- or high-grade NHL were treated with a new therapeutic scheme which included Mitoxantrone, Etoposide, Cyclophosphamide and Prednisone (MiCEP). Twenty-eight patients achieved a complete remission, ten patients partial remission (overall response rate of 93%) and two cases were resistant. The overall survival was 66% with a median follow-up of 24 months from diagnosis: three patients relapsed after a median period of 7 months. The relapse-free survival was 92% after a median follow-up of 18 months. Blood and other organ toxicity was acceptable and 12% of patients experienced a grade 4 (WHO) neutropenia. In conclusion, MiCEP was effective in inducing a good remission rate with moderate toxic effects in elderly patients with intermediate- or high-grade NHL and appears to be a useful combination to use in this group of patients.


Scandinavian Journal of Rheumatology | 1987

Cutaneous fibrinolytic activity in primary hypertrophic osteoarthropathy.

Marco Matucci-Cerinic; Torello Lotti; I. Jajic; S. Di Lollo; L. Brunetti; D. Orlic

Cutaneous fibrinolytic activity was investigated in 13 patients affected with Primary Hypertrophic Osteoarthropathy in the advanced phase. Biopsies were taken from periungueal skin of the ippocratic finger and from the dorsum of the first phalanx: cutaneous fibrinolytic activity was investigated with Todds autohistographic method as modified by Lotti et al., showing increased activity in periungueal skin (10/13) and normal in the apparently uninvolved skin (9/13). We suggest that the increase in plasminogen activator activity, in the advanced phase of the disease, may be related to the increased growth of the connective tissue that is characteristic of the disease.

Collaboration


Dive into the S. Di Lollo's collaboration.

Top Co-Authors

Avatar

A. Papucci

University of Florence

View shared research outputs
Top Co-Authors

Avatar

E. Brizzi

University of Florence

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G. Bellesi

University of Florence

View shared research outputs
Top Co-Authors

Avatar

Ilario Menchi

Santa Maria Nuova Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge